<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article310</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/PCPT" style="display:block; margin-bottom:10px;">PCPT Original</a></li>
<h2><strong>PCPT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Finasteride in the Prevention of Prostate Cancer".The New England Journal of Medicine. 2003. <br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
<br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Funding<br/>
10 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does finasteride reduce the risk of prostate cancer in men 55 years of age or older?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Finasteride reduced the risk of prostate cancer by 24.8% but was associated with an increased risk of high-grade prostate cancer and sexual side effects, whereas urinary symptoms were more common in men receiving placebo.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Finasteride is known to inhibit the conversion of testosterone to dihydrotestosterone, potentially affecting the development of prostate cancer. This double-blind, placebo-controlled trial aimed to test the effects of finasteride on the prevention of prostate cancer in men 55 years and older.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
At the time of publication, guidelines for the use of finasteride as a preventive measure against prostate cancer were not established.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Placebo-controlled, double-blind, randomized controlled trial<br/>
- N=18,882 men aged 55 or older<br/>
- Finasteride 5 mg per day vs. placebo<br/>
- Mean follow-up: 7 years (terminated 15 months early)<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Men aged 55 years or older<br/>
- Normal digital rectal examination<br/>
- Prostate-specific antigen (PSA) level of 3.0 ng per milliliter or lower<br/>
<br/>
Exclusion Criteria<br/>
- Clinically significant coexisting conditions that would prevent compliance<br/>
- American Urological Association symptom score of 20 or higher<br/>
<br/>
Baseline Characteristics<br/>
- Median age, race or ethnicity, family history of prostate cancer, PSA level at randomization not detailed in the Wiki<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Finasteride 5 mg daily or placebo for seven years<br/>
- Annual digital rectal examinations and PSA measurements<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
- Prevalence of prostate cancer during the seven-year study period (18.4% in the finasteride group vs. 24.4% in the placebo group)<br/>
<br/>
Secondary Outcomes<br/>
- Tumors with a Gleason grade of 7-10 were more common in the finasteride group (37.0%) than in the placebo group (22.2%)<br/>
- Sexual side effects more common in finasteride group<br/>
- Urinary symptoms more common in placebo group<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported in part by Public Health Service grants from the National Cancer Institute.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Full publication in The New England Journal of Medicine<br/>
- Other related research and reviews for deeper insights on finasteride and prostate cancer prevention
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
